FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308731908> ?p ?o ?g. }

• W4308731908 abstract "Type 2 diabetes (T2D) is a progressive disease often associated with comorbidities that complicate the management of T2D and affect the achievement of treatment targets. However, adherence to guidelines and individualized treatments can potentially improve treatment outcomes. This study assessed the association between different glucose lowering and lipid lowering medication lines and the achievement of treatment targets with different comorbidities among a T2D cohort in North Karelia, Finland (2011-12 to 2015-16).The data on all diagnosed T2D patients (n = 10,190) in North Karelia were collated retrospectively from regional electronic health records (EHRs). Analyses were performed considering the age, sex, and comorbidities such as cardiovascular diseases (CVD) and any mental disorders (AMD). We analyzed the trends in using glucose lowering and lipid lowering medications and the effect of changes in medication on the achievement of treatment targets among different patient groups.Metformin was the most common treatment in all patient groups. The use of only metformin declined and the use of metformin and/or other non-insulin medications increased during the follow-up. A Combination of insulin and non-insulin medication was mostly used by T2D patients with both cardiovascular diseases and mental disorders (T2D + CVD + AMD), and the use of insulin increased among this group in follow-up. Achievement of the glucose treatment target deteriorated even after the intensification of medication among all patient groups during the follow-up. A considerably higher number of patients with T2D + AMD and T2D + CVD + AMD did not use lipid lowering medication when compared to the T2D + CVD patients both at baseline and follow-up. However, the achievement of the LDL treatment target improved during the follow-up.Achievement of the glucose target deteriorated even after the intensification of treatment, and especially among patients with multiple diseases. Many T2D patients with AMD and CVD remained without lipid lowering medication, which needs further attention." @default.
• W4308731908 created "2022-11-15" @default.
• W4308731908 creator A5015822352 @default.
• W4308731908 creator A5026047281 @default.
• W4308731908 creator A5027454073 @default.
• W4308731908 creator A5041121152 @default.
• W4308731908 creator A5050088159 @default.
• W4308731908 creator A5072939656 @default.
• W4308731908 creator A5089433699 @default.
• W4308731908 date "2022-11-09" @default.
• W4308731908 modified "2023-10-09" @default.
• W4308731908 title "Mode of treatments and achievement of treatment targets among type 2 diabetes patients with different comorbidities – a register-based retrospective cohort study in Finland" @default.
• W4308731908 cites W1526927233 @default.
• W4308731908 cites W1942610538 @default.
• W4308731908 cites W1973517048 @default.
• W4308731908 cites W1975588287 @default.
• W4308731908 cites W1980496426 @default.
• W4308731908 cites W2037866347 @default.
• W4308731908 cites W2074346614 @default.
• W4308731908 cites W2093975835 @default.
• W4308731908 cites W2111824270 @default.
• W4308731908 cites W2116285515 @default.
• W4308731908 cites W2123862325 @default.
• W4308731908 cites W2128050336 @default.
• W4308731908 cites W2148951021 @default.
• W4308731908 cites W2160088494 @default.
• W4308731908 cites W2166678637 @default.
• W4308731908 cites W2169007215 @default.
• W4308731908 cites W2198247989 @default.
• W4308731908 cites W2275928777 @default.
• W4308731908 cites W2296983088 @default.
• W4308731908 cites W2302447233 @default.
• W4308731908 cites W2337454357 @default.
• W4308731908 cites W2340898396 @default.
• W4308731908 cites W2397486247 @default.
• W4308731908 cites W2770035155 @default.
• W4308731908 cites W2777318825 @default.
• W4308731908 cites W2805386774 @default.
• W4308731908 cites W2806521060 @default.
• W4308731908 cites W2808642612 @default.
• W4308731908 cites W2810597988 @default.
• W4308731908 cites W2894993577 @default.
• W4308731908 cites W2938758635 @default.
• W4308731908 cites W2955840062 @default.
• W4308731908 cites W2974788498 @default.
• W4308731908 cites W2977158547 @default.
• W4308731908 cites W2996204986 @default.
• W4308731908 cites W3093913648 @default.
• W4308731908 cites W3096063139 @default.
• W4308731908 cites W3117724216 @default.
• W4308731908 cites W4211080275 @default.
• W4308731908 cites W4232847804 @default.
• W4308731908 cites W4236126199 @default.
• W4308731908 cites W4253996779 @default.
• W4308731908 cites W4254445254 @default.
• W4308731908 cites W4376463373 @default.
• W4308731908 doi "https://doi.org/10.1186/s12875-022-01889-3" @default.
• W4308731908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36352358" @default.
• W4308731908 hasPublicationYear "2022" @default.
• W4308731908 type Work @default.
• W4308731908 citedByCount "0" @default.
• W4308731908 crossrefType "journal-article" @default.
• W4308731908 hasAuthorship W4308731908A5015822352 @default.
• W4308731908 hasAuthorship W4308731908A5026047281 @default.
• W4308731908 hasAuthorship W4308731908A5027454073 @default.
• W4308731908 hasAuthorship W4308731908A5041121152 @default.
• W4308731908 hasAuthorship W4308731908A5050088159 @default.
• W4308731908 hasAuthorship W4308731908A5072939656 @default.
• W4308731908 hasAuthorship W4308731908A5089433699 @default.
• W4308731908 hasBestOaLocation W43087319081 @default.
• W4308731908 hasConcept C126322002 @default.
• W4308731908 hasConcept C134018914 @default.
• W4308731908 hasConcept C167135981 @default.
• W4308731908 hasConcept C187212893 @default.
• W4308731908 hasConcept C201903717 @default.
• W4308731908 hasConcept C2777180221 @default.
• W4308731908 hasConcept C2779159551 @default.
• W4308731908 hasConcept C2779306644 @default.
• W4308731908 hasConcept C2780323712 @default.
• W4308731908 hasConcept C555293320 @default.
• W4308731908 hasConcept C71924100 @default.
• W4308731908 hasConcept C72563966 @default.
• W4308731908 hasConceptScore W4308731908C126322002 @default.
• W4308731908 hasConceptScore W4308731908C134018914 @default.
• W4308731908 hasConceptScore W4308731908C167135981 @default.
• W4308731908 hasConceptScore W4308731908C187212893 @default.
• W4308731908 hasConceptScore W4308731908C201903717 @default.
• W4308731908 hasConceptScore W4308731908C2777180221 @default.
• W4308731908 hasConceptScore W4308731908C2779159551 @default.
• W4308731908 hasConceptScore W4308731908C2779306644 @default.
• W4308731908 hasConceptScore W4308731908C2780323712 @default.
• W4308731908 hasConceptScore W4308731908C555293320 @default.
• W4308731908 hasConceptScore W4308731908C71924100 @default.
• W4308731908 hasConceptScore W4308731908C72563966 @default.
• W4308731908 hasIssue "1" @default.
• W4308731908 hasLocation W43087319081 @default.
• W4308731908 hasLocation W43087319082 @default.
• W4308731908 hasLocation W43087319083 @default.
• W4308731908 hasLocation W43087319084 @default.
• W4308731908 hasLocation W43087319085 @default.

• next